Stifel on Thursday initiated coverage on Immunic Inc. IMUX, a late-stage biotechnology company developing oral therapies for ...
Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
Zacks Investment Research on MSN
TGTX completes enrollment in Phase III study on subcutaneous Briumvi
TG Therapeutics TGTX announced that it has completed enrollment in the phase III study evaluating the subcutaneous ...
In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...
A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...
The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect ...
Basel, 30 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability ...
Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results